Company intelligence / Profile preview
Cleara Biotech
Utrecht, Utrecht, Netherlandsclearabiotech.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead compounds CL04177 and CL04183 show efficacy in 2D cells, 3D organoid and mouse in vivo models for metastatic colon cancer and triple-negative breast cancer, with favorable pharmacokinetics and tissue distribution in mice. The company aims to enter clinical trials by 2024.
- Therapeutic areas
- OtherOncology
- Modalities
- D-amino acid peptides
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Cleara Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cleara Biotech.